StockDuty ← Dashboard Aug 10, 2026 11:29 AM ET
CatalystFDA/Bio

Silence Therapeutics shares surge ahead of divesiran Phase 2 results call

Surge reflects investor anticipation of imminent divesiran Phase 2 data release.

What changed
Why it matters
Surge reflects investor anticipation of imminent divesiran Phase 2 data release.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →